Bioverativ Inc. is an American multinational

biotechnology Biotechnology is a multidisciplinary field that involves the integration of natural sciences and Engineering Science, engineering sciences in order to achieve the application of organisms and parts thereof for products and services. Specialists ...

company that specializes in the discovery, development, and delivery of therapies for the treatment of haemophilia. Bioverativ competes with Baxalta (acquired by Shire Plc in 2016),

Pfizer Pfizer Inc. ( ) is an American Multinational corporation, multinational Pharmaceutical industry, pharmaceutical and biotechnology corporation headquartered at The Spiral (New York City), The Spiral in Manhattan, New York City. Founded in 184 ...

and Novo Nordisk. The company traded on the NASDAQ exchange under the ticker symbol BIVV until

Sanofi Sanofi S.A. is a French Multinational corporation, multinational pharmaceutical and healthcare company headquartered in Paris, France. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 200 ...

completed its acquisition on March 8, 2018.

History

In May 2016

Biogen Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the discovery, development, and delivery of the treatment of neurological diseases to patients worldwide. Biogen ope ...

announced that it would spin off its hemophilia drug business (Eloctate and Alprolix) into a separate public company. In August, Biogen announced they would call the spun off company ''Bioverativ'' to show heritage with Biogen, and would be spun off in early 2017. On December 22, the

Securities and Exchange Commission The United States Securities and Exchange Commission (SEC) is an independent agency of the United States federal government, created in the aftermath of the Wall Street crash of 1929. Its primary purpose is to enforce laws against market m ...

approved Bioverativ's registration statement, with the official separation date of the two companies being pegged at February 2017. In February, Biogen investors received a special dividend of one share of Bioverativ stock for every two shares of Biogen stock held as of January 17. Bioverativ began trading on January 12, 2017. In May 2017, the company announced it would acquire True North Therapeutics for $825 million, strengthening Bioverativ's pipeline with the acquisition of TNT009 – a treatment for cold agglutinin disease. In January 2018,

announced that it would acquire the business, for $11.6 billion.

Acquisition history

The following is an illustration of the company's major mergers and acquisitions and historical predecessors:

Products

The company has two current products; Alprolix and Eloctate, both products provided combined revenues of $604 million in 2015, and $640 million in the first nine months of 2016 (contributing to ~6% of Biogens' total revenue. These products are marketed in the United States, European Union, Japan, Canada and Australia.

References

{{reflist American companies established in 2016 Companies formerly listed on the Nasdaq Multinational companies headquartered in the United States Biotechnology companies established in 2016 Biotechnology companies of the United States Corporate spin-offs Sanofi 2018 mergers and acquisitions Pharmaceutical companies disestablished in 2018 American subsidiaries of foreign companies